doi: 10.1038/s41587-021-00980-x.
'Super-antibodies' could curb COVID-19 and help avert future pandemics
Affiliations
- PMID: 34158667
- PMCID: PMC8218965
- DOI: 10.1038/s41587-021-00980-x
Item in Clipboard
'Super-antibodies' could curb COVID-19 and help avert future pandemics
Nat Biotechnol.
2021 Jul.
Erratum in
-
Publisher Correction: 'Super-antibodies' could curb COVID-19 and help avert future pandemics.Nat Biotechnol. 2021 Jul;39(7):893. doi: 10.1038/s41587-021-00997-2. Nat Biotechnol. 2021. PMID: 34188223 Free PMC article. No abstract available.
Abstract
Companies are designing next-generation antibodies modeled on those taken from unique individuals whose immune systems can neutralize any COVID-19 variant—and related coronaviruses, too.
Figures
Antibodies attacking a coronavirus (artist’s impression). Super-antibodies that can neutralize even the most worrying versions of SARS-CoV-2 could be used both to prevent and to treat infections. Kiyoshi Takahase Segundo / Alamy Stock Photo
Similar articles
-
Publisher Correction: 'Super-antibodies' could curb COVID-19 and help avert future pandemics.Nat Biotechnol. 2021 Jul;39(7):893. doi: 10.1038/s41587-021-00997-2. Nat Biotechnol. 2021. PMID: 34188223 Free PMC article. No abstract available.
-
Applicability of the CURB-65 pneumonia severity score for outpatient treatment of COVID-19.J Infect. 2020 Sep;81(3):e96-e98. doi: 10.1016/j.jinf.2020.05.049. Epub 2020 May 29. J Infect. 2020. PMID: 32474039 Free PMC article.
-
CURB-65 may serve as a useful prognostic marker in COVID-19 patients within Wuhan, China: a retrospective cohort study.Epidemiol Infect. 2020 Oct 1;148:e241. doi: 10.1017/S0950268820002368. Epidemiol Infect. 2020. PMID: 32998791 Free PMC article.
-
Passive immunotherapy of viral infections: 'super-antibodies' enter the fray.Nat Rev Immunol. 2018 May;18(5):297-308. doi: 10.1038/nri.2017.148. Epub 2018 Jan 30. Nat Rev Immunol. 2018. PMID: 29379211 Free PMC article. Review.
-
Significance of super spreader events in COVID-19.Indian J Public Health. 2020 Jun;64(Supplement):S139-S141. doi: 10.4103/ijph.IJPH_495_20. Indian J Public Health. 2020. PMID: 32496245 Review.
Cited by
-
Sotrovimab use in Japanese inpatients with COVID-19: post-infusion adverse events.BMC Infect Dis. 2022 Dec 3;22(1):902. doi: 10.1186/s12879-022-07889-z. BMC Infect Dis. 2022. PMID: 36461006 Free PMC article. Review.
-
The COVID-19/Tuberculosis Syndemic and Potential Antibody Therapy for TB Based on the Lessons Learnt From the Pandemic.Front Immunol. 2022 Feb 15;13:833715. doi: 10.3389/fimmu.2022.833715. eCollection 2022. Front Immunol. 2022. PMID: 35242137 Free PMC article. Review.
-
Monoclonal antibody therapies in the management of SARS-CoV-2 infection.Expert Opin Investig Drugs. 2022 Jan;31(1):41-58. doi: 10.1080/13543784.2022.2030310. Epub 2022 Feb 14. Expert Opin Investig Drugs. 2022. PMID: 35164631 Free PMC article.
-
Vaccinal antibodies: Fc antibody engineering to improve the antiviral antibody response and induce vaccine-like effects.Hum Vaccin Immunother. 2021 Dec 2;17(12):5532-5545. doi: 10.1080/21645515.2021.1985891. Epub 2021 Nov 29. Hum Vaccin Immunother. 2021. PMID: 34844516 Free PMC article. Review.
-
Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency.Front Immunol. 2021 Oct 26;12:750386. doi: 10.3389/fimmu.2021.750386. eCollection 2021. Front Immunol. 2021. PMID: 34764961 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
